DK2705365T3 - Immunoassay til direkte bestemmelse af antigenindhold i produkter indeholdende adjuvans-koblede antigenpartikler - Google Patents

Immunoassay til direkte bestemmelse af antigenindhold i produkter indeholdende adjuvans-koblede antigenpartikler Download PDF

Info

Publication number
DK2705365T3
DK2705365T3 DK12705431.0T DK12705431T DK2705365T3 DK 2705365 T3 DK2705365 T3 DK 2705365T3 DK 12705431 T DK12705431 T DK 12705431T DK 2705365 T3 DK2705365 T3 DK 2705365T3
Authority
DK
Denmark
Prior art keywords
antigen
immunoglobulin
particles
coupled
adjuvant
Prior art date
Application number
DK12705431.0T
Other languages
English (en)
Inventor
Erica Helena Maria Kerkvliet
Original Assignee
Hal Allergy Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hal Allergy Holding B V filed Critical Hal Allergy Holding B V
Application granted granted Critical
Publication of DK2705365T3 publication Critical patent/DK2705365T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (10)

1
1. Fremgangsmåde til bestemmelse af styrken af et produkt indeholdende antigen-koblede adjuvanspartikler, hvilken fremgangsmåde omfatter trinene: a) kontakt mellem produktet indeholdende antigen-koblede adjuvanspartikler og immunglobulinmolekyler, der kan genkende antigenet under betingelser, der tillader antigen-immunglobulin-binding; b) tilvejebringelse af en overflade med antigenet, uden adjuvanset, immobili-seret derpå; c) kontakt mellem det immunglobulin-kontaktede produkt fra trin (a) og overfladen i trin (b) under betingelser, der tillader antigen-immunglobulin-binding; d) fjernelse af ikke-bundne immunglobulinmolekyler og antigen-koblede ad-juvanspartikler-bundne immunglobulinmolekyler; e) detektering af antigen-bundne immunglobulinmolekyler for derved at bestemme styrken af et produkt indeholdende antigen-koblede adjuvanspartikler ved bestemmelse af 50% IgG-inhiberingen under anvendelse af en dosis-re-spons-kurve; hvor de antigen-koblede adjuvanspartikler er antigen-koblede aluminiumpartikler eller antigen-koblede tyrosi nparti kier, og hvor immunglobulinet er IgG.
2. Fremgangsmåde ifølge krav 1, hvor produktet er en vaccine eller et immunterapeutisk middel.
3. Fremgangsmåde ifølge krav 1, hvor det nævnte aluminium er valgt fra gruppen bestående af aluminiumhydroxid, alhydrogel, aluminiumphosphat, kalium-aluminiumsulfat og alun.
4. Fremgangsmåde ifølge ethvert af kravene 1 til 3, hvor antigenet er et allergen.
5. Fremgangsmåde ifølge ethvert af kravene 1 til 4, hvor trin (e) omfatter kontakt mellem de antigen-bundne immunglobulinmolekyler og et andet immun-globulinmolekyle, der kan genkende det antigen-bundne immunglobulinmolekyle 2 under betingelser, der tillader antigen-bundet immunglobulinmolekyle-andet im-munglobulinmolekyle-binding og detektering af antigen-bundet immunglobulinmolekyle-andet immunglobulinmolekyle-binding.
6. Fremgangsmåde ifølge krav 5, hvor det andet immunglobulin omfatter en detekterbar mærkning.
7. Fremgangsmåde ifølge krav 6, hvor mærkningen er et enzym, fortrinsvis HRP.
8. Fremgangsmåde ifølge ethvert af kravene 1 til 7, hvor overfladen er tilvejebragt med en ELISA-plade.
9. Fremgangsmåde ifølge ethvert af kravene 1 til 8, hvor produktet indeholdende antigen-koblede adjuvanspartikler er en suspension.
10. Fremgangsmåde ifølge ethvert af kravene 1 til 9, hvor trin (d) omfatter én eller flere ganges vask af overfladen.
DK12705431.0T 2011-01-14 2012-01-31 Immunoassay til direkte bestemmelse af antigenindhold i produkter indeholdende adjuvans-koblede antigenpartikler DK2705365T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011050433 2011-01-14
PCT/IB2012/050447 WO2012095834A1 (en) 2011-01-14 2012-01-31 Immunoassay for direct determination of antigen content of products comprising adjuvant-coupled-antigen particles

Publications (1)

Publication Number Publication Date
DK2705365T3 true DK2705365T3 (da) 2016-10-24

Family

ID=45755426

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12705431.0T DK2705365T3 (da) 2011-01-14 2012-01-31 Immunoassay til direkte bestemmelse af antigenindhold i produkter indeholdende adjuvans-koblede antigenpartikler

Country Status (5)

Country Link
US (1) US20130302837A1 (da)
DK (1) DK2705365T3 (da)
ES (1) ES2594895T3 (da)
PT (1) PT2705365T (da)
WO (1) WO2012095834A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2715899C1 (ru) * 2019-02-21 2020-03-04 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ количественного определения в вакцинном препарате антигена, адсорбированного на частицах гидроксида алюминия
CN112798787A (zh) * 2019-11-14 2021-05-14 安徽智飞龙科马生物制药有限公司 狂犬病疫苗抗原含量检测方法及试剂或试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
AU2770001A (en) * 2000-01-07 2001-07-24 Aventis Pasteur Competitive enzyme immunoassay for assessing total antigen content of aluminum-adsorbed antigens
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
CA2464527A1 (en) * 2001-10-26 2003-08-14 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
US7867715B2 (en) * 2003-08-05 2011-01-11 Alk-Abello A/S Method of evaluating the immunological activity of a vaccine
US20080254041A1 (en) * 2003-09-11 2008-10-16 Novozymes A/S Method for Selecting an Immunotherapeutic Preparation

Also Published As

Publication number Publication date
WO2012095834A1 (en) 2012-07-19
US20130302837A1 (en) 2013-11-14
PT2705365T (pt) 2016-09-19
ES2594895T3 (es) 2016-12-23

Similar Documents

Publication Publication Date Title
JP4690928B2 (ja) イムノクロマト法によるアレルゲンの検出方法
CN103837674A (zh) 特异性IgE抗体的检测方法、该方法所使用的试剂盒以及该试剂盒的制备和使用方法
CN110873791A (zh) 一种基于双标记信号放大的间接背景荧光胶体金免疫层析试纸条及其应用
CN107328938A (zh) 胃蛋白酶原和抗幽门螺杆菌抗体检测方法及其试剂盒
CN107132359A (zh) 胃蛋白酶原ⅰ和胃蛋白酶原ⅱ检测方法及其试剂盒
Bai et al. Development of a new fluorescence immunochromatography strip for detection of chloramphenicol residues in chicken muscles
KR101866844B1 (ko) 면역분석에서 시약의 반응성을 조절하기 위한 공동 결합
US20090325148A1 (en) Bead Array Reader Based-Hemagglutination and Hemagglutination Inhibition Assay
CN110763848A (zh) ELISA检测唾液样品中SAα2-6Gal糖链含量的方法
DK2705365T3 (da) Immunoassay til direkte bestemmelse af antigenindhold i produkter indeholdende adjuvans-koblede antigenpartikler
Ye et al. Establishment of N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC) modified biochip enabling concurrent detection of serum infectious antibodies in neuroborreliosis
CN109459570A (zh) 一种快速检测人体血液中铅离子的胶体金免疫试纸条制备方法
Descamps et al. A Case study of development, validation, and acceptance of a non-animal method for assessing human vaccine potency
Riches-Duit et al. Characterisation of diphtheria monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay
Riches-Duit et al. Characterisation of tetanus monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay
McDonald et al. Development of a custom pentaplex sandwich immunoassay using Protein-G coupled beads for the Luminex® xMAP® platform
CN110763849A (zh) ELISA检测唾液样品中SAα2-3Gal糖链含量的方法
Necchi et al. Development of FAcE (Formulated Alhydrogel competitive ELISA) method for direct quantification of OAg present in Shigella sonnei GMMA-based vaccine and its optimization using Design of Experiments approach
EP2705365B1 (en) Immunoassay for direct determination of antigen content of products comprising adjuvant-coupled-antigen particles
CN106771189B (zh) 一种油佐剂疫苗的快速定性定量检测方法
KR20120088238A (ko) 원유 내 항생제 검출 키트 및 이를 이용한 원유의 항생제 검출 방법
CN106980020A (zh) 降钙素原和c‑反应蛋白二合一测定试剂盒及制法
KR20190059089A (ko) 측방유동 면역 분석 기반의 항ccp 항체 및 류마티스인자를 이용한 류마티스 관절염 진단 방법
Cao et al. Detection of subtle differences in analogous viral capsid proteins by allowing unrestricted specific interaction in solution competition ELISA
Takada et al. Development of an indirect competitive ELISA for the detection of ABO blood group antigens